Results 121 to 130 of about 160,542 (279)
, 2017 Sulsal Haque,1,2 Mahender Yellu,1,2 Jaskirat Randhawa,1,2 Nooshin Hashemi-Sadraei1,2 1Division of Hematology/Oncology, Department of Medicine, University of Cincinnati, 2University of Cincinnati Cancer Institute, Cincinnati, OH, USA Abstract: Head and ...
Randhawa J +3 more
core
International Journal of Cancer, EarlyView.Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia +4 more
wiley +1 more source
IgE-mediated anaphylaxis induced by pembrolizumab
International audienceThe increasing use of biologics in cancer treatment is associated with an increase in drug-related hypersensitivity reactions (HSR) of varying severity.
Perotin, Jeanne-Marie +3 more
core +1 more source
Journal of Cancer Research and Clinical OncologyBackground Although pembrolizumab has been shown to be effective, its high price has prevented it from being widely used. Especially in the real world, the application situation is still uncertain.
Ning Wan +15 more
doaj +1 more source
Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond
International Journal of Cancer, EarlyView.Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...
Yago Garitaonaindia +11 more
wiley +1 more source
Pembrolizumab-induced myasthenia gravis: Two patients’ experiences
Checkpoint inhibitors are increasingly used to treat patients with gynecologic malignancies and can cause rare and unusual side effects, also known as immunotoxicities, that are rarely observed in patients receiving traditional immunotherapy.
Robert Higgins +5 more
core +1 more source
, 2019 Immunotherapy has revolutionized lung cancer management. Our study focused on the efficacy of first-line pembrolizumab for treatment of non-small-cell lung cancer by summarizing 4 phase III clinical trials.
Kim, Miso +7 more
core +1 more source
International Journal of Cancer, EarlyView.Although immune checkpoint inhibitors (ICI) have transformed metastatic melanoma treatment, thromboembolic events (TEEs) remain a serious complication. Moreover, existing risk assessment models were developed prior to ICI use and lack clinical validation.
Tim Zell +12 more
wiley +1 more source
Acquired lipodystrophy following use of pembrolizumab
This case report details a 65-year-old female with Hashimoto's hypothyroidism and stage III melanoma who developed acquired generalized lipodystrophy (AGL), a rare immune-mediated adverse event, following pembrolizumab treatment.
Maya Weitzen +5 more
core +1 more source
Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients
Pharmacological ResearchBackground: Pembrolizumab is a standard first-line treatment for metastatic non–small cell lung cancer (NSCLC). Although approved dosing regimens achieve near-maximal PD-1 receptor occupancy in clinical trials, variability in pembrolizumab exposure in ...
Cristina Martínez-Toledo +27 more
doaj +1 more source